company background image

Becton Dickinson NYSE:BDX Stock Report

Last Price


Market Cap







02 Oct, 2022


Company Financials +
BDX fundamental analysis
Snowflake Score
Future Growth2/6
Past Performance3/6
Financial Health3/6

BDX Stock Overview

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide.

Becton Dickinson Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Becton Dickinson
Historical stock prices
Current Share PriceUS$222.83
52 Week HighUS$280.62
52 Week LowUS$222.61
1 Month Change-11.87%
3 Month Change-11.51%
1 Year Change-8.93%
3 Year Change-11.96%
5 Year Change12.50%
Change since IPO2,746.53%

Recent News & Updates

Sep 26

BD, Certest Biotec launch monkeypox test

Becton, Dickinson (NYSE:BDX) and partner CerTest Biotec said on Monday their molecular polymerase chain reaction (PCR) assay for monkeypox virus was now commercially available globally, including in the United States, for research use only applications by laboratories. BD said it was working to submit a clinical test for monkeypox virus for emergency used authorization by the U.S. Food and Drug Administration as soon as possible. The CerTest Viasure Monkeypox virus PCR Detection RUO assay for the BD MAX System is offered in a lyophilized format. The BD MAX System is a platform that performs nucleic acid extraction and real-time PCR that provide results for up to 24 samples across multiple syndromes in less than three hours.

Sep 13

Becton, Dickinson launches next-gen prefillable vaccine syringe BD Effivax

Becton, Dickinson and Company (NYSE:BDX) said it launched a next-generation glass prefillable syringe (PFS) for vaccine PFS with tightened specifications for processability and contamination. BD Effivax is designed in collaboration with pharmaceutical companies to meet the complex and evolving needs of vaccine manufacturing, the company said in a Sept. 13 press release. "As biopharmaceutical companies continue to rapidly grow their vaccine pipelines, demand for PFS is accelerating across the globe – given their proven ability to facilitate faster administration, support dose sparing and reduce vaccine waste," said Eric Borin, Worldwide President of BD Pharmaceutical Systems.

Shareholder Returns

BDXUS Medical EquipmentUS Market

Return vs Industry: BDX exceeded the US Medical Equipment industry which returned -31.2% over the past year.

Return vs Market: BDX exceeded the US Market which returned -23.2% over the past year.

Price Volatility

Is BDX's price volatile compared to industry and market?
BDX volatility
BDX Average Weekly Movement2.9%
Medical Equipment Industry Average Movement8.5%
Market Average Movement6.8%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market2.8%

Stable Share Price: BDX is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 3% a week.

Volatility Over Time: BDX's weekly volatility (3%) has been stable over the past year.

About the Company

189775,000Tom Polen

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company’s BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers.

Becton Dickinson Fundamentals Summary

How do Becton Dickinson's earnings and revenue compare to its market cap?
BDX fundamental statistics
Market CapUS$63.55b
Earnings (TTM)US$1.90b
Revenue (TTM)US$20.08b


P/E Ratio


P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
BDX income statement (TTM)
Cost of RevenueUS$10.59b
Gross ProfitUS$9.49b
Other ExpensesUS$7.59b

Last Reported Earnings

Jun 30, 2022

Next Earnings Date


Earnings per share (EPS)6.66
Gross Margin47.25%
Net Profit Margin9.46%
Debt/Equity Ratio64.2%

How did BDX perform over the long term?

See historical performance and comparison



Current Dividend Yield


Payout Ratio
We’ve recently updated our valuation analysis.


Is BDX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score


Valuation Score 5/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BDX?

Other financial metrics that can be useful for relative valuation.

BDX key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue3.9x
Enterprise Value/EBITDA14.2x
PEG Ratio2.1x

Price to Earnings Ratio vs Peers

How does BDX's PE Ratio compare to its peers?

BDX PE Ratio vs Peers
The above table shows the PE ratio for BDX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average46.4x
BSX Boston Scientific
ISRG Intuitive Surgical
SYK Stryker
EW Edwards Lifesciences
BDX Becton Dickinson

Price-To-Earnings vs Peers: BDX is good value based on its Price-To-Earnings Ratio (33.4x) compared to the peer average (46.4x).

Price to Earnings Ratio vs Industry

How does BDX's PE Ratio compare vs other companies in the US Medical Equipment Industry?

Price-To-Earnings vs Industry: BDX is expensive based on its Price-To-Earnings Ratio (33.4x) compared to the US Medical Equipment industry average (32.2x)

Price to Earnings Ratio vs Fair Ratio

What is BDX's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BDX PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio33.4x
Fair PE Ratio38.8x

Price-To-Earnings vs Fair Ratio: BDX is good value based on its Price-To-Earnings Ratio (33.4x) compared to the estimated Fair Price-To-Earnings Ratio (38.8x).

Share Price vs Fair Value

What is the Fair Price of BDX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: BDX ($222.83) is trading below our estimate of fair value ($377.03)

Significantly Below Fair Value: BDX is trading below fair value by more than 20%.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

Future Growth

How is Becton Dickinson forecast to perform in the next 1 to 3 years based on estimates from 14 analysts?

Future Growth Score


Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: BDX's forecast earnings growth (15.8% per year) is above the savings rate (1.9%).

Earnings vs Market: BDX's earnings (15.8% per year) are forecast to grow faster than the US market (14.8% per year).

High Growth Earnings: BDX's earnings are forecast to grow, but not significantly.

Revenue vs Market: BDX's revenue (4.8% per year) is forecast to grow slower than the US market (7.7% per year).

High Growth Revenue: BDX's revenue (4.8% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: BDX's Return on Equity is forecast to be low in 3 years time (15.1%).

Discover growth companies

Past Performance

How has Becton Dickinson performed over the past 5 years?

Past Performance Score


Past Performance Score 3/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: BDX has a large one-off loss of $546.0M impacting its June 30 2022 financial results.

Growing Profit Margin: BDX's current net profit margins (9.5%) are higher than last year (7.8%).

Past Earnings Growth Analysis

Earnings Trend: BDX's earnings have grown significantly by 29.2% per year over the past 5 years.

Accelerating Growth: BDX's earnings growth over the past year (27.9%) is below its 5-year average (29.2% per year).

Earnings vs Industry: BDX earnings growth over the past year (27.9%) exceeded the Medical Equipment industry -0.2%.

Return on Equity

High ROE: BDX's Return on Equity (7.8%) is considered low.

Discover strong past performing companies

Financial Health

How is Becton Dickinson's financial position?

Financial Health Score


Financial Health Score 3/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: BDX's short term assets ($9.5B) exceed its short term liabilities ($7.1B).

Long Term Liabilities: BDX's short term assets ($9.5B) do not cover its long term liabilities ($20.6B).

Debt to Equity History and Analysis

Debt Level: BDX's net debt to equity ratio (54.1%) is considered high.

Reducing Debt: BDX's debt to equity ratio has reduced from 151% to 64.2% over the past 5 years.

Debt Coverage: BDX's debt is not well covered by operating cash flow (16%).

Interest Coverage: BDX's interest payments on its debt are well covered by EBIT (8.1x coverage).

Balance Sheet

Discover healthy companies


What is Becton Dickinson current dividend yield, its reliability and sustainability?

Dividend Score


Dividend Score 4/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage


Current Dividend Yield

Dividend Yield vs Market

Becton Dickinson Dividend Yield vs Market
How does Becton Dickinson dividend yield compare to the market?
SegmentDividend Yield
Company (Becton Dickinson)1.6%
Market Bottom 25% (US)1.7%
Market Top 25% (US)4.7%
Industry Average (Medical Equipment)1.9%
Analyst forecast in 3 Years (Becton Dickinson)1.9%

Notable Dividend: BDX's dividend (1.56%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.67%).

High Dividend: BDX's dividend (1.56%) is low compared to the top 25% of dividend payers in the US market (4.73%).

Stability and Growth of Payments

Stable Dividend: BDX's dividends per share have been stable in the past 10 years.

Growing Dividend: BDX's dividend payments have increased over the past 10 years.

Earnings Payout to Shareholders

Earnings Coverage: With its reasonable payout ratio (51.7%), BDX's dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: With its reasonable cash payout ratio (67.7%), BDX's dividend payments are covered by cash flows.

Discover strong dividend paying companies


How experienced are the management team and are they aligned to shareholders interests?


Average management tenure


Tom Polen (49 yo)





Mr. Thomas E. Polen, Jr., also known as Tom, serves as Chief Executive Officer and Director at Becton, Dickinson and Company since January 28, 2020. Mr. Polen has been President of Becton, Dickinson and Co...

CEO Compensation Analysis

Tom Polen's Compensation vs Becton Dickinson Earnings
How has Tom Polen's remuneration changed compared to Becton Dickinson's earnings?
DateTotal Comp.SalaryCompany Earnings
Jun 30 2022n/an/a


Mar 31 2022n/an/a


Dec 31 2021n/an/a


Sep 30 2021US$14mUS$1m


Jun 30 2021n/an/a


Mar 31 2021n/an/a


Dec 31 2020n/an/a


Sep 30 2020US$12mUS$952k


Jun 30 2020n/an/a


Mar 31 2020n/an/a


Dec 31 2019n/an/a


Sep 30 2019US$6mUS$900k


Jun 30 2019n/an/a


Mar 31 2019n/an/a


Dec 31 2018n/an/a


Sep 30 2018US$6mUS$850k


Jun 30 2018n/an/a


Mar 31 2018n/an/a


Dec 31 2017n/an/a


Sep 30 2017US$4mUS$761k


Jun 30 2017n/an/a


Mar 31 2017n/an/a


Dec 31 2016n/an/a


Sep 30 2016US$3mUS$651k


Compensation vs Market: Tom's total compensation ($USD14.19M) is about average for companies of similar size in the US market ($USD13.04M).

Compensation vs Earnings: Tom's compensation has increased by more than 20% in the past year.

Leadership Team

Experienced Management: BDX's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.

Board Members

Experienced Board: BDX's board of directors are considered experienced (5.9 years average tenure).


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Recent Insider Transactions

NYSE:BDX Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
06 May 22SellUS$121,600David HickeyIndividual475US$256.00
08 Feb 22SellUS$228,500Claire Fraser-LiggettIndividual841US$271.70
16 Dec 21SellUS$711,195Betty LarsonIndividual2,789US$255.00
07 Dec 21SellUS$58,250Thomas SpoerelIndividual233US$250.00

Ownership Breakdown

What is the ownership structure of BDX?
Owner TypeNumber of SharesOwnership Percentage
Private Companies44,9410.02%
State or Government131,7510.05%
Individual Insiders417,9710.1%
General Public29,758,27410.4%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 56.94% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
T. Rowe Price Group, Inc.
The Vanguard Group, Inc.
BlackRock, Inc.
State Street Global Advisors, Inc.
Wellington Management Group LLP
Morgan Stanley Investment Management Inc.
Parnassus Investments, LLC
Massachusetts Financial Services Company
Geode Capital Management, LLC
Wells Fargo & Company, Securities and Brokerage Investments
Ninety One UK Limited
Generation Investment Management LLP
Fiera Capital Corporation
Northern Trust Global Investments
BNY Mellon Asset Management
J.P. Morgan Asset Management, Inc.
Invesco Ltd.
Franklin Resources, Inc.
Norges Bank Investment Management
Mackenzie Financial Corporation
Columbia Management Investment Advisers, LLC
Veritas Asset Management LLP
Longview Partners (Guernsey) Ltd
ClearBridge Investments, LLC
Legal & General Investment Management Limited

Company Information

Becton, Dickinson and Company's employee growth, exchange listings and data sources

Key Information

  • Name: Becton, Dickinson and Company
  • Ticker: BDX
  • Exchange: NYSE
  • Founded: 1897
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Implied Market Cap: US$63.550b
  • Shares outstanding: 285.20m
  • Website:

Number of Employees


  • Becton, Dickinson and Company
  • 1 Becton Drive
  • Franklin Lakes
  • New Jersey
  • 07417-1880
  • United States


TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BDXNYSE (New York Stock Exchange)YesCommon StockUSUSDJan 1968
BOXDB (Deutsche Boerse AG)YesCommon StockDEEURJan 1968
BOXXTRA (XETRA Trading Platform)YesCommon StockDEEURJan 1968
912061BRSE (Berne Stock Exchange)YesCommon StockCHCHFJan 1968
0R19LSE (London Stock Exchange)YesCommon StockGBUSDJan 1968
BDX *BMV (Bolsa Mexicana de Valores)YesCommon StockMXMXNJan 1968
BDXWBAG (Wiener Boerse AG)YesCommon StockATEURJan 1968
BOXETLX (Eurotlx)YesCommon StockITEURJan 1968
B1DX34BOVESPA (Bolsa de Valores de Sao Paulo)BDR EACH 5 REPR 1 COMBRBRLJan 2020
BDXBNYSE (New York Stock Exchange)6% DP CONV PFD BUSUSDMay 2020

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/10/02 00:00
End of Day Share Price2022/09/30 00:00
Annual Earnings2021/09/30

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.